MRP Capital Investments LLC Purchases 4,975 Shares of Solventum Co. (NYSE:SOLV)

MRP Capital Investments LLC grew its holdings in Solventum Co. (NYSE:SOLV - Free Report) by 93.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,275 shares of the company's stock after acquiring an additional 4,975 shares during the quarter. MRP Capital Investments LLC's holdings in Solventum were worth $679,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Investment House LLC grew its holdings in shares of Solventum by 111.3% during the 4th quarter. Investment House LLC now owns 76,171 shares of the company's stock worth $5,032,000 after purchasing an additional 40,130 shares in the last quarter. Xponance Inc. lifted its position in Solventum by 9.8% in the fourth quarter. Xponance Inc. now owns 21,014 shares of the company's stock worth $1,388,000 after purchasing an additional 1,879 shares during the period. Boston Partners acquired a new position in shares of Solventum in the 4th quarter valued at $110,378,000. Generali Asset Management SPA SGR bought a new position in shares of Solventum during the 4th quarter worth about $659,000. Finally, Thrivent Financial for Lutherans boosted its position in shares of Solventum by 37.9% during the 4th quarter. Thrivent Financial for Lutherans now owns 12,721 shares of the company's stock valued at $863,000 after acquiring an additional 3,498 shares in the last quarter.

Solventum Trading Up 0.9 %

NYSE SOLV traded up $0.67 during trading hours on Tuesday, hitting $74.87. The company's stock had a trading volume of 1,083,684 shares, compared to its average volume of 1,427,904. The stock has a fifty day moving average of $75.38 and a 200 day moving average of $71.73. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The firm has a market capitalization of $12.95 billion and a P/E ratio of 27.23. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $85.92.

Remove Ads

Analyst Ratings Changes

A number of research analysts have commented on SOLV shares. Bank of America raised their price target on shares of Solventum from $80.00 to $85.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 26th. The Goldman Sachs Group upped their price objective on shares of Solventum from $63.00 to $71.00 and gave the stock a "sell" rating in a research note on Monday, March 3rd. Piper Sandler lifted their target price on shares of Solventum from $75.00 to $84.00 and gave the company a "neutral" rating in a research note on Friday, February 28th. Wells Fargo & Company increased their price target on Solventum from $73.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Friday, February 28th. Finally, Mizuho lifted their price objective on Solventum from $70.00 to $82.00 and gave the company a "neutral" rating in a research report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has given a buy rating to the company's stock. According to MarketBeat, Solventum currently has a consensus rating of "Hold" and a consensus target price of $79.86.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.